Rtw Investments Adds $5M in Aquestive Therapeutics, Inc. ($AQST)
RTW Investments boosted its position in Aquestive Therapeutics by 18.8%, now holding 7.43 million shares.
Key Points
- RTW Investments increased its stake in Aquestive Therapeutics by 18.8%, adding 1.18 million shares for a total of 7.43 million shares worth $30.97 million.
- Aquestive Therapeutics, traded on NasdaqGM under ticker AQST, has a market cap of about $523.1 million and a 52-week trading range of $2.93 to $7.55.
- Insiders, including Gregory Brown and Marco Taglietti, bought 50,500 shares each on June 10, 2026, while analysts maintain a positive outlook with multiple 'buy' ratings.
RTW Investments has increased its stake in Aquestive Therapeutics, Inc. (NasdaqGM: AQST), adding 1.18 million shares. This move, reflected in a recent Form 13F filing with the SEC, brings its total holdings to 7.43 million shares, representing an 18.8% increase. The value of this position is approximately $30.97 million as of the filing date.
What Changed in RTW Investments' Aquestive Therapeutics Position
RTW Investments boosted its holdings in Aquestive Therapeutics by 18.8%, adding 1.18 million shares to its portfolio. Previously holding 6.25 million shares, the fund now owns 7.43 million shares, valued at about $30.97 million. This adjustment is part of its strategy as reported for the quarter ending March 31, 2026.
Other Institutional Activity in Aquestive Therapeutics
Several other institutional investors have also adjusted their positions in Aquestive Therapeutics. Bratton Capital Management, L.P. maintained its position with 9.81 million shares valued at $40.72 million. BlackRock, Inc. slightly reduced its stake by 266,331 shares, now holding 7.51 million shares worth $31.16 million. Vanguard Capital Management LLC established a new position with 4.44 million shares valued at $18.44 million. Federated Hermes, Inc. increased its holdings by 907,517 shares, bringing its total to 2.94 million shares valued at $12.20 million. Meanwhile, Balyasny Asset Management L.P. significantly boosted its stake by 1.93 million shares, now holding 2.90 million shares worth $12.04 million.
Aquestive Therapeutics Stock Snapshot
Shares of Aquestive Therapeutics (NasdaqGM: AQST) traded near $4.17 recently. The company has a market capitalization of approximately $523.1 million. Although it is not profitable, with no meaningful P/E ratio, its forward P/E is noted as -9.27. The stock has a 52-week low of $2.93 and a high of $7.55. Its 50-day moving average is $4.14, while the 200-day moving average stands at $4.88. The company maintains a current ratio of 4.1 and a quick ratio of 3.7, indicating solid liquidity.
Recent Earnings
In its most recent earnings report, Aquestive Therapeutics posted revenue of $50.27 million, reflecting a growth rate of 65.7%. However, the company recorded a net margin of -137.1%, with earnings per share (EPS) of -$0.61. Investors are looking ahead to the next earnings release scheduled for August 11, 2026.
Insider Buying and Selling at Aquestive Therapeutics, Inc.
On June 10, 2026, several insiders at Aquestive Therapeutics made notable transactions. Gregory Brown, Julie Krop, Marco Taglietti, and John Cochran each purchased 50,500 shares. Abigail Jenkins sold 50,500 shares on the same day. These transactions were not conducted under a Rule 10b5-1 plan.
Analysts Set New Price Targets
Analysts remain optimistic about Aquestive Therapeutics. On November 7, 2025, Piper Sandler maintained its 'buy' rating with a target price of $8. JMP Securities also kept its 'buy' rating with a target of $12 on October 9, 2025. Oppenheimer reiterated its 'buy' rating with an $8 target on September 8, 2025. The consensus target price among analysts is approximately $8.89, with 9 analysts providing opinions.
About Aquestive Therapeutics
Aquestive Therapeutics, Inc. is a pharmaceutical company based in Warren, New Jersey. It develops and markets innovative drug delivery solutions, focusing on oral film formulations for various treatments, including epilepsy and opioid dependence. The company is led by CEO Daniel Barber and employs 147 people. Its pipeline includes several products in different stages of clinical trials, leveraging its PharmFilm technology.
Bottom Line
RTW Investments' increased stake in Aquestive Therapeutics signals confidence in the company's potential. Investors closely monitor such filings to understand fund strategies, though these positions are historical snapshots and may not reflect current holdings. Aquestive's innovative approach in drug delivery and its current market position make it a point of interest for both institutional investors and analysts.
See Also
This instant news alert was generated by automated narrative technology and financial data from Trueearnings and public regulatory filings. It is for informational purposes only and is not financial advice.